Literature DB >> 23897128

Missed opportunities for depression screening in patients with arthritis in the United States.

Mary E Margaretten1, Patricia Katz, Gabriela Schmajuk, Edward Yelin.   

Abstract

BACKGROUND: Arthritis affects 20 % of the adult US population and is associated with comorbid depression. Depression screening guidelines have been endorsed for high-risk groups, including persons with arthritis, in the hopes that screening will increase recognition and use of appropriate interventions.
OBJECTIVE: To examine national rates of depression and depression screening for patients with arthritis between 2006 and 2010. PARTICIPANTS AND
DESIGN: We used nationally representative cross-sections of ambulatory visits in the United States from the National Ambulatory Medical Care Survey from 2006 to 2010, which included 18,507 visits with a diagnosis of arthritis. When weighted to the US population, this total represents approximately 644 million visits. MEASUREMENTS: Visits where arthritis was listed among diagnoses. Outcomes were survey-weighted estimates of depression and prevalence of depression screening among patients with arthritis across patient and physician characteristics. KEY
RESULTS: Of the 644,419,374 visits with arthritis listed, 83,574,127 (13 %) were associated with a comorbid diagnosis of depression. The odds ratio for comorbid depression with arthritis was 1.42 (95 % CI 1.3, 1.5). Depression screening occurred at 3,835,000 (1 %) visits associated with arthritis. When examining the rates of depression screening between ambulatory visits with and without arthritis listed, there was no difference in depression screening rates; both were approximately 1 %. There was no difference in screening rates by provider type. Compared to visits with other common, chronic conditions, the prevalence of depression at arthritis visits was high (13 per 100 visits), although the prevalence of depression screening at arthritis visits was low (0.68 per 100 visits).
CONCLUSIONS: Despite the high prevalence of depression with arthritis, screening for depression was performed at few arthritis visits, representing missed opportunities to detect a common, serious comorbidity. Improved depression screening by providers would identify affected patients, and may lead to appropriate interventions such as mental health referrals and/or treatment with anti-depressants.

Entities:  

Mesh:

Year:  2013        PMID: 23897128      PMCID: PMC3832729          DOI: 10.1007/s11606-013-2541-y

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  45 in total

1.  Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis.

Authors:  Chris Dickens; Linda McGowan; David Clark-Carter; Francis Creed
Journal:  Psychosom Med       Date:  2002 Jan-Feb       Impact factor: 4.312

2.  Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics.

Authors:  J L Barton; L Trupin; D Schillinger; S A Gansky; C Tonner; M Margaretten; V Chernitskiy; J Graf; J Imboden; E Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-09       Impact factor: 4.794

3.  Depression screening as a quality indicator.

Authors:  Daniel J Luchins
Journal:  Ment Health Fam Med       Date:  2010-06

4.  Depression in patients with rheumatoid arthritis: description, causes and mechanisms.

Authors:  Mary Margaretten; Laura Julian; Patricia Katz; Edward Yelin
Journal:  Int J Clin Rheumtol       Date:  2011

Review 5.  Priorities among effective clinical preventive services: results of a systematic review and analysis.

Authors:  Michael V Maciosek; Ashley B Coffield; Nichol M Edwards; Thomas J Flottemesch; Michael J Goodman; Leif I Solberg
Journal:  Am J Prev Med       Date:  2006-07       Impact factor: 5.043

6.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

Authors:  R L Spitzer; K Kroenke; J B Williams
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

7.  National Ambulatory Medical Care Survey: 2007 summary.

Authors:  Chun-Ju Hsiao; Donald K Cherry; Paul C Beatty; Elizabeth A Rechtsteiner
Journal:  Natl Health Stat Report       Date:  2010-11-03

8.  Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis.

Authors:  Dennis C Ang; Hyon Choi; Kurt Kroenke; Frederick Wolfe
Journal:  J Rheumatol       Date:  2005-06       Impact factor: 4.666

9.  Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997.

Authors:  Edward Yelin; Louise Murphy; Miriam G Cisternas; Aimee J Foreman; David J Pasta; Charles G Helmick
Journal:  Arthritis Rheum       Date:  2007-05

10.  Depression increases risk of incident myocardial infarction among Veterans Administration patients with rheumatoid arthritis.

Authors:  Jeffrey F Scherrer; Katherine S Virgo; Angelique Zeringue; Kathleen K Bucholz; Theodore Jacob; Robert G Johnson; William R True; Robert M Carney; Kenneth E Freedland; Hong Xian; Liron Caplan; Jay McDonald; Seth A Eisen
Journal:  Gen Hosp Psychiatry       Date:  2009-05-09       Impact factor: 3.238

View more
  3 in total

1.  Associations of alcohol consumption and mental health with the prevalence of arthritis among US adults: data from the 2012 National Health Interview Survey.

Authors:  Ke-Sheng Wang; Xuefeng Liu; Liang Wang
Journal:  Rheumatol Int       Date:  2014-03-26       Impact factor: 2.631

2.  Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression?

Authors:  Yusuke Miwa; Hidekazu Furuya; Ryo Yanai; Tsuyoshi Kasama; Kenji Sanada
Journal:  Eur J Rheumatol       Date:  2018-01-22

3.  The Relationship between the Serum Oxytocin Levels, Disease Activity, the ADLs and the QOL in Patients with Rheumatoid Arthritis.

Authors:  Yusuke Miwa; Hidekazu Furuya; Ryo Yanai; Tsuyoshi Kasama; Kenji Sanada
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.